Masroor Badshah | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Dr. Masroor Badshah | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Monash University | Australia

Author Profile

Scopus

Orcid

Google Scholar

Early Academic Pursuits

Dr. Masroor Badshah’s academic foundation is marked by a rigorous pursuit of medicine and anatomical sciences. Beginning with his degree in Medicine and Surgery, he developed an early research interest in the clinical relevance of anatomy, completing projects on skin diseases and vascular variations. His postgraduate studies at the University of Dundee expanded his expertise into human anatomy, where he defended a dissertation on carotid artery variations. This path led him to Monash University, where he earned his doctorate in medicine, focusing on oxytocin signaling in regulating the myogenic tone of the prostate and bladder. These early endeavors established a solid base for his later contributions to pharmacology and biomedical sciences.

Professional Endeavors

Dr. Badshah’s professional journey spans multiple countries, reflecting both versatility and international recognition. He began his teaching career as a lecturer and assistant professor in human anatomy at medical institutions in Pakistan before moving to Scotland and later Australia. His teaching associate roles at Monash University and research assistantship at the Monash Institute of Pharmaceutical Sciences allowed him to mentor students, design innovative teaching methodologies, and participate in collaborative research. His clinical internships in medicine and surgery also provided him with practical exposure that enriched his academic and research perspectives.

Contributions and Research Focus

At the core of Dr. Badshah’s career lies his dedication to advancing knowledge in pharmacology, toxicology, and pharmaceutical sciences. His doctoral work investigated the pharmacological role of oxytocin receptor antagonists in bladder and prostate function, with implications for overactive bladder treatments. His broader research includes studies in human surface anatomy, craniofacial asymmetry, morphometry of skeletal structures, and the clinical relevance of anatomical variations. By combining anatomical precision with pharmacological inquiry, he bridges the gap between foundational science and therapeutic application.

Accolades and Recognition

Throughout his career, Dr. Badshah has been honored with prestigious awards and scholarships, including the Monash Graduate Scholarship, Faculty International Tuition Scholarship, and the University of Dundee Tuition Scholarship. His academic excellence is reflected in multiple publications in peer-reviewed journals such as Biomedicines, Clinical Anatomy, and the Italian Journal of Anatomy and Embryology. He has also been a frequent presenter at international conferences, where his research findings on oxytocin signaling and anatomical morphometry have received recognition from the scientific community.

Impact and Influence

Dr. Badshah’s influence extends beyond research publications to shaping the next generation of medical and pharmaceutical scientists. His teaching philosophy emphasizes critical thinking, active participation, and evidence-based learning. By integrating innovative methodologies and fostering a collaborative learning environment, he has left a lasting impression on his students across different institutions. His work in surface anatomy and pharmacological sciences contributes to both clinical education and translational research, making his influence both academic and practical.

Legacy and Future Contributions

As a researcher with interdisciplinary expertise, Dr. Badshah’s legacy lies in his ability to merge anatomy with pharmacology for improved clinical outcomes. His ongoing research into bladder and prostate physiology offers potential breakthroughs in addressing urological disorders. Looking ahead, he aims to expand his collaborations globally, secure independent research leadership, and explore translational aspects of his work that could lead to therapeutic innovations. His legacy will continue to inspire young researchers and contribute to the evolution of biomedical sciences.

Publication


Investigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within Obese and Non-Obese Rats
Authors: Masroor Badshah, Jibriil Ibrahim, Nguok Su, Penny Whiley, Sarah M. Turpin-Nolan, Khaled A. Elnahriry, Ralf Middendorff, Michael Whittaker, Betty Exintaris
Journal: Biomedicines
Year: 2025


Age-Dependent Effects of Oxytocin and Oxytocin Receptor Antagonists on Bladder Contractions: Implications for the Treatment of Overactive Bladder Syndrome
Authors: Masroor Badshah, Jibriil Ibrahim, Nguok Su, Penny Whiley, Ralf Middendorff, Michael Whittaker, Betty Exintaris
Journal: Biomedicines
Year: 2024


The Effects of Age on Prostatic Responses to Oxytocin and the Effects of Antagonists
Authors: Masroor Badshah, Jibriil Ibrahim, Nguok Su, Penny Whiley, Michael Whittaker, Betty Exintaris
Journal: Biomedicines
Year: 2023


Type of Treatment Supporters in Successful Completion of Tuberculosis Treatment: A Retrospective Cohort Study in Pakistan
Authors: Sana Hussain, Jamshed Hasnain, Zareen Hussain, Masroor Badshah, Hafeez Siddique, Christina Fiske, April Pettit
Journal: The Open Infectious Diseases Journal
Year: 2018


Morphology of the Human Hard Palate: A Study on Dry Skulls
Authors: Masroor Badshah, Roger Soames, Muhammad Jaffar Khan, Jamshaid Hasnain
Journal: Italian Journal of Anatomy and Embryology
Year: 2018


Conclusion

Dr. Masroor Badshah exemplifies the qualities of a dedicated academic, skilled researcher, and inspiring mentor. His career trajectory reflects a balance of teaching, research, and clinical exposure, with a focus on advancing pharmacology and anatomical sciences. His publications, conference presentations, and mentoring of students have strengthened his academic influence, while his research contributions offer practical applications in medicine. With a strong foundation and a vision for global collaboration, Dr. Badshah’s journey positions him as a leading figure in biomedical and pharmaceutical research, making his recognition as a distinguished researcher both timely and well-deserved.

Inmaculada Gilaberte | Medicine and Dentistry | Best Researcher Award

Dr. Inmaculada Gilaberte | Medicine and Dentistry | Best Researcher Award

FAES Farma | Spain

Author Profile

Scopus

🌱 Early Academic Pursuits

Dr. Inmaculada Gilaberte’s academic journey is rooted in a commitment to excellence and medical advancement. She initially pursued education in clinical research, equipping herself with in-depth knowledge and skills in therapeutic areas such as neuroscience and immunology. Her academic foundation was further strengthened by certifications, including a lecturer certification from the Spanish Quality Register Agency (ANECA), and advanced leadership programs from institutions like Stanford and MIT. These formative experiences shaped her growth mindset, laying the groundwork for a career dedicated to precision, patient-centered care, and effective team collaboration.

💼 Professional Endeavors

Throughout her career, Dr. Gilaberte has held prominent roles in major pharmaceutical companies such as FAES FARMA, Takeda, TiGenix, Roche, and Lilly, with positions spanning from Clinical Research Physician to Director of Clinical Research. She has led various departments, managed global teams, and directed clinical trials across multiple therapeutic areas, including gastroenterology, immunology, cardiology, and pain management. Her strategic guidance has driven several landmark projects forward, including the advancement of microbiome and cell therapies from preclinical to first-in-human trials, demonstrating her expertise in transforming innovative therapies into viable treatment options.

🧬 Contributions and Research Focus

Dr. Gilaberte has made notable contributions to clinical research, particularly in stem cell therapy, immunology, and neuroscience. Her pioneering work on Darvadstrocel, an allogeneic adipose-derived mesenchymal stem cell therapy, led to significant strides in treating perianal fistulas and positioned her as a leader in regenerative medicine. She has been instrumental in launching global clinical trials, developing target product profiles (TPP), and submitting regulatory applications for FDA and EMA approvals. With a robust publication record, including 66 papers indexed in PubMed, she continues to contribute to scientific literature, sharing her findings and advancing the field of biomedicine.

🏆 Accolades and Recognition

Dr. Gilaberte’s excellence has been recognized through numerous awards across her roles in clinical development and leadership. Her achievements include multiple awards for her work in the clinical progression of innovative therapies and successful drug submissions to global regulatory bodies. She has received recognition for her strategic contributions to the Darvadstrocel trials and for advancing neuroscience programs in Alzheimer’s disease. Her leadership has earned her high regard in the industry, with acknowledgments from institutions and colleagues alike.

🌍 Impact and Influence

Dr. Gilaberte’s impact extends beyond her immediate professional roles. Her contributions to clinical science have enhanced treatment options for patients with complex diseases, and her leadership has shaped clinical strategies in multinational pharmaceutical companies. She has also promoted effective collaboration across global, cross-functional teams, fostering a diverse and inclusive work environment that prioritizes patient needs. Her initiatives in regulatory compliance, risk management, and data integration have set new standards for clinical operations, solidifying her influence as a thought leader in her field.

📜 Legacy and Future Contributions

Looking ahead, Dr. Gilaberte’s legacy is one of commitment to advancing patient care through innovation, collaboration, and strategic foresight. Her future endeavors are poised to make an enduring impact, with ongoing research and leadership contributions that will shape the future of clinical development. Her philanthropic work, such as building a nursery in Uganda, highlights her dedication to global well-being beyond her professional achievements. Dr. Gilaberte continues to inspire the next generation of clinical researchers, ensuring that her legacy of precision, empathy, and patient-first innovation will endure.

 

Publications


📄 Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial

  • Authors: Esteban Jódar-Gimeno, Jose Luis Pérez-Castrillón, Ján Nociar, Michal Lojka, Dimitar Nikolov, Fernando Cereto-Castro, Snežana Novković, Umberto Tarantino, Nadia Mehsen-Cetre, Paula Arranz, Cristina Martínez Ostalé, Aintzane García-Bea, Inmaculada Gilaberte
  • Journal: Nutrients
  • Year: 2024

📄 Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial

  • Authors: Coimbra, J., Puntes, M., Molina, P., Arranz, P., Sánchez, C.
  • Journal: European Journal of Pharmaceutical Sciences
  • Year: 2024

📄  Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions

  • Authors: Román, M., Ochoa, D., Martin, S., Arranz, P., Sánchez, C.
  • Journal: Drugs in R and D
  • Year: 2024

📄  Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases

  • Authors: Karki, C., Latremouille-Viau, D., Gilaberte, I., Romdhani, H., Lightner, A.L.
  • Journal: PharmacoEconomics
  • Year: 2023

📄  Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn’s Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial

  • Authors: Garcia-Olmo, D., Gilaberte, I., Binek, M., Spinelli, A., Panés, J.
  • Journal: Diseases of the Colon and Rectum
  • Year: 2022